On March 5, 2024 Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, reported it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 5-10, 2024, at the San Diego Convention Center (Press release, Myeloid Therapeutics, MAR 5, 2024, View Source [SID1234640826]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details follow:

Title: In vivo programming of natural killer cells and T cells using mRNA delivered cytotoxic chimeric antigen receptors
Date & Time: Monday Apr 8, 2024, 9:00 AM – 12:30 PM
Location: Poster Section 2
Session Category: Immunology
Session Title: CAR-NK, NK Engagers, and NK Modulators
Poster Board Number: 2
Published Abstract Number: 1319

Title: In vivo Immune Cell Programming Using mRNA-LNP Chimeric Antigen Receptors
Date & Time: Monday Apr 8, 2024, 9:00 AM – 12:30 PM
Location: Poster Section 2
Session Category: Immunology
Session Title: CAR-NK, NK Engagers, and NK Modulators
Poster Board Number: 4
Published Abstract Number: 1321

Title: Preclinical & clinical activity of autologous mRNA engineered chimeric antigen receptor monocytes for targeted cancer immunotherapy
Date & Time: Monday Apr 8, 2024, 1:30 PM – 5:00 PM
Location: Poster Section 39
Session Category: Clinical Research
Session Title: Adoptive Cellular Therapy 1
Poster Board Number: 18
Published Abstract Number: 3612